Provided by Tiger Trade Technology Pte. Ltd.

NovoCure

10.03
-0.1100-1.08%
Pre-market: 10.00-0.0300-0.30%08:00 EST
Volume:1.21M
Turnover:12.13M
Market Cap:1.12B
PE:-6.24
High:10.20
Open:10.12
Low:9.82
Close:10.14
52wk High:22.95
52wk Low:9.82
Shares:111.98M
Float Shares:94.15M
Volume Ratio:0.54
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6074
EPS(LYR):-1.5638
ROE:-50.60%
ROA:-8.30%
PB:3.29
PE(LYR):-6.41

Loading ...

Wedbush Reaffirms Their Hold Rating on NovoCure (NVCR)

TIPRANKS
·
Feb 07

Maintaining Buy on NovoCure: Viewing CMS Billing Revocation as a Temporary Administrative Setback with Limited Long-Term Impact

TIPRANKS
·
Feb 06

Novocure Inc. Faces CMS Billing Privilege Revocation

Reuters
·
Feb 05

Novocure Price Target Maintained With a $18.00/Share by Wedbush

Dow Jones
·
Jan 15

Novocure Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 13

NovoCure (NVCR) Gets a Hold from Wells Fargo

TIPRANKS
·
Jan 13

Novocure Limited : H.c. Wainwright Cuts Target Price to $39 From $42

THOMSON REUTERS
·
Jan 13

Novocure Names Frank Leonard as Chief Executive Officer

Reuters
·
Jan 13

NovoCure Reports Rise in Q4 Preliminary Revenue

MT Newswires Live
·
Jan 12

Novocure reports preliminary Q4 revenue $174.4M, consensus $168.93M

TIPRANKS
·
Jan 12

Novocure Reports Record 2025 Revenue with 8% Annual Growth

Reuters
·
Jan 12

Novocure Ltd - in Q1 2026, Intends to Stop Reporting New Prescriptions Received in Indications Which Were Commercially Available for Over a Year

THOMSON REUTERS
·
Jan 12

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

THOMSON REUTERS
·
Jan 12

Novocure Ltd FY2025 REV View $651.2 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

Novocure Ltd - Will Continue to Report Active Patients on Therapy Segmented by Product (Optune Gio, Optune Lua) and Material Market

THOMSON REUTERS
·
Jan 12

Novocure Ltd - Prelim 2025 Net Revenues of $655 Mln

THOMSON REUTERS
·
Jan 12

It’s Earnings Warning Season. How to Profit From Others’ Misery

Dow Jones
·
Jan 01

Novocure to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 22, 2025

Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy?

Simply Wall St.
·
Dec 10, 2025

How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm

Simply Wall St.
·
Dec 02, 2025